Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New registry aims to sharpen use of precision radiation in advanced cancer

NCT ID NCT02170181

First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 31 times

Summary

This study created a registry of 149 cancer patients who received a precise type of radiation called SBRT. The goal was to track how doctors use SBRT in four situations: for cancer that has spread to a few spots, after chemotherapy, before starting chemotherapy, or when cancer returns in a previously treated area. By collecting this information, researchers hope to learn which patients benefit most and improve future treatment guidelines.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • University of Texas Southwestern Medical Center

    Dallas, Texas, 75239, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Stereotactic body radiation therapy (SBRT)

What this could lead to

If successful, this registry could help doctors better understand when and how to use SBRT for cancer that has spread, potentially improving treatment decisions.

What could go wrong

This is an observational registry, not a treatment trial, so it won't directly test if SBRT works better than other options. Results may not apply to all cancer types.

Conditions

The condition(s) this trial relates to.

kidney cancer lung neoplasm neoplasm prostate cancer Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.